Entwicklung eines neuen Nanopartikel-basierten Impfstoffs zur Behandlung chronisch-persistierender Infektionen (C01)

在该项目中，已经开发了含有T细胞表位肽和TLR配体的基于纳米颗粒的疫苗。用这种功能化的纳米颗粒接种疫苗诱导了有效的病毒特异性T细胞应答，并减少了Fried病毒（FV）模型中的慢性逆转录病毒载量。这种非常成功的治疗性疫苗接种现在应与免疫检查点阻断疗法组合，以在FV感染的小鼠中消除病毒。此外，纳米颗粒疫苗接种策略将在慢性感染HIV-1的人源化BLT小鼠的临床前模型中进行测试。还将开发临床相关的给药策略（药物、口服胶囊）。

In this project a nanoparticle-based vaccine that contains T cell epitope peptides and TLR ligands has been developed. Vaccination with this functionalized nanoparticles induced potent virus-specific T cell responses and reduced chronic retroviral loads in the Fried virus (FV) model. This very successful therapeutic vaccination shall now be combined with immune checkpoint blocking therapies to aim for virus elimination in FV infected mice. In addition, the nanoparticle vaccination strategy will be tested in the preclinical model of humanized BLT mice chronically infected with HIV-1. Clinically relevant delivery strategies (supporitories, oral administered capsules) will also be developed.